Skip to main
MRNA
MRNA logo

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 9%
Hold 55%
Sell 27%
Strong Sell 0%

Bulls say

Moderna's financial projections indicate substantial growth, with product sales anticipated to increase from $1.73 billion in 2025 to $2.15 billion in 2026, reflecting strong demand for its multiple mRNA candidates. The company has also bolstered its financial standing through a $1.5 billion debt deal, which provides enhanced flexibility for navigating uncertainties and capitalizing on future opportunities. Moreover, improvements in manufacturing efficiency are expected to restore gross margins to approximately 50%, up from a pandemic low of 30%, potentially driving further profitability in the years ahead.

Bears say

Moderna is experiencing significant revenue declines, with COVID vaccine sales projected at $6.7 billion for 2023, a substantial drop from $18 billion in 2022, driven by waning vaccination rates and increasing competition in the respiratory vaccine landscape. The company has adjusted its long-term revenue outlook for COVID-related products from $3.5 billion to $2.5 billion annually, exacerbated by low sales expectations in the European market and slow progress in its pipeline outside of respiratory vaccines. As a result, the valuation of its COVID and COVID+flu vaccines has been reduced from $11.70 billion to $10.50 billion, reflecting ongoing uncertainty and material short-term headwinds.

Moderna (MRNA) has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 9% recommend Buy, 55% suggest Holding, 27% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 11 analysts, Moderna (MRNA) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.